$75.60

+1.20 (+1.61%)

Weekly Expected Move ±3.2%

$71 $73 $76 $78 $80

NYSE · Healthcare · Medical - Devices · Tech Score Sell · Power 50 · $10.2B mcap · 134M float · 1.21% daily turnover · Short 74% of daily vol

Edge Score

Quantitative competitive moat analysis scoring five pillars of durable advantage — cost leadership, brand intangibles, switching costs, network effects, and efficient scale — using industry percentile rankings on a 0–100 scale.

NARROW EDGE

58.9 / 100

NoneWeakNarrowWide

Primary source: Network Effects · ROIC: 12.3% · 5Y Avg: 10.3%

Cost Advantage

Intangibles

Switching Cost

Network Effect

Scale

The Edge Score quantifies a company's competitive moat using five pillars: Cost Advantage (20%, operating margin and SG&A efficiency vs industry peers), Intangible Assets (25%, gross margin premium, R&D intensity, brand pricing power), Switching Costs (25%, revenue stability, earnings consistency, customer retention proxied by operating leverage), Network Effects (15%, revenue growth with expanding margins, market share dominance), and Efficient Scale (15%, market concentration, ROIC sustainability). Each pillar is scored 0–100 using industry percentile rankings, then weighted into a composite. Wide ≥ 70, Narrow ≥ 55, Weak ≥ 40, None < 40. GMED has a Narrow competitive edge (58.9/100) — meaningful but not impregnable advantages over competitors. The primary source of advantage is Network Effects. ROIC of 12.3% suggests modest returns relative to capital deployed.

Analyst Insights

Wall Street analyst consensus based on price targets and buy/sell/hold recommendations from institutional research coverage over the trailing 12 months.

Analyst Price Targets

$85

Low

$85

Avg Target

$85

High

Based on 1 analyst since Aug 6, 2026 earnings

Analyst Recommendations

Strong Buy: 0Buy: 26Hold: 9Sell: 1Strong Sell: 0

Rating Summary

ConsensusBuy

Avg Target$92.67

Analysts6

Price Target Change History

Date	Firm	Analyst	Old	New	Change	Upside @ Call	Stock@Call
2026-10-01	RBC Capital	Shagun Singh	$115	$85	-30	+13.5%	$74.90
2026-07-28	UBS	—	Initiated	$82	—	+4.8%	$78.25
2026-07-16	Truist Financial	Richard Newitter	$115	$100	-15	+23.7%	$80.85
2026-07-13	RBC Capital	Shagun Singh	$100	$115	+15	+44.6%	$79.53
2026-07-08	BMO Capital	—	Initiated	$94	—	+23.4%	$76.20
2026-07-08	Stifel Nicolaus	—	$64	$80	+16	+1.5%	$78.83
2026-06-15	Piper Sandler	—	$115	$100	-15	+24.4%	$80.39
2026-05-08	Needham	—	$112	$117	+5	+48.5%	$78.77
2026-05-08	Wells Fargo	Larry Biegelsen	$78	$103	+25	+21.1%	$85.08
2026-02-25	Truist Financial	Richard Newitter	$85	$115	+30	+21.9%	$94.32
2026-01-30	Needham	—	$71	$112	+41	+24.1%	$90.22
2026-01-26	Cowen & Co.	—	Initiated	$110	—	+18.3%	$92.98
2026-01-09	Canaccord Genuity	—	$105	$112	+7	+18.4%	$94.62
2026-01-08	Piper Sandler	Matt O'Brien	$80	$115	+35	+27.0%	$90.54
2025-12-17	RBC Capital	Shagun Singh	$88	$100	+12	+16.6%	$85.79
2025-12-17	Canaccord Genuity	Caitlin Cronin	$90	$105	+15	+22.4%	$85.79
2025-10-28	Stifel Nicolaus	Thomas Stephan	$61	$64	+3	+0.9%	$63.45
2025-10-10	RBC Capital	—	$73	$88	+15	+52.9%	$57.55
2024-12-02	Morgan Stanley	Kallum Titchmarsh	$71	$100	+29	+16.9%	$85.52
2024-08-28	BTIG	Ryan Zimmerman	$72	$77	+5	+7.3%	$71.73
2024-08-07	Wells Fargo	Vik Chopra	$82	$78	-4	+10.6%	$70.53
2024-07-15	Morgan Stanley	Drew Ranieri	$78	$71	-7	-0.1%	$71.07
2024-05-29	BTIG	Ryan Zimmerman	$60	$72	+12	+9.9%	$65.49
2024-05-20	Piper Sandler	Matt O'Brien	$75	$80	+5	+24.2%	$64.40
2024-03-18	BTIG	Ryan Zimmerman	Initiated	$60	—	+16.2%	$51.65
2023-09-19	Stifel Nicolaus	Mathew Blackman	Initiated	$61	—	+15.0%	$53.04
2023-01-06	Morgan Stanley	—	$62	$78	+16	+8.4%	$71.97
2022-12-20	Truist Financial	—	$71	$85	+14	+19.1%	$71.36
2022-12-12	Wells Fargo	—	Initiated	$82	—	+12.1%	$73.13
2022-08-05	Piper Sandler	—	Initiated	$75	—	+27.4%	$58.85
2022-07-20	Truist Financial	—	Initiated	$71	—	+21.7%	$58.35
2022-07-15	Morgan Stanley	—	$68	$62	-6	+10.2%	$56.27
2022-05-12	Morgan Stanley	—	Initiated	$68	—	+11.2%	$61.16
2022-05-11	RBC Capital	—	Initiated	$73	—	+21.7%	$59.97
2022-05-11	Needham	—	Initiated	$71	—	+16.0%	$61.22
2021-12-12	Bank of America Securities	Craig Bijou	Initiated	$80	—	+16.0%	$68.96
2021-08-04	Canaccord Genuity	Kyle Rose	Initiated	$90	—	+12.6%	$79.90
2021-08-04	Citigroup	Matthew Henriksson	Initiated	$93	—	+16.4%	$79.90

Financial Rating

Composite financial health rating (A+ to F) based on discounted cash flow valuation, return on equity, return on assets, debt-to-equity leverage, and relative P/E and P/B multiples.

A-

Oct 02, 2026

DCF

ROE

ROA

D/E

P/E

P/B

The Financial Rating evaluates six fundamental factors — discounted cash flow (DCF) valuation, return on equity (ROE), return on assets (ROA), debt-to-equity leverage (D/E), and relative price-to-earnings (P/E) and price-to-book (P/B) multiples — each scored 1–5. GMED receives an overall rating of A-. Strongest factors: DCF (5/5), ROE (4/5), ROA (5/5). Areas of concern: D/E (2/5), P/E (2/5).

Rating Change History

Date	From	To
2026-10-01	A	A-
2026-02-26	A+	A
2026-02-24	A	A+
2026-02-18	A-	A
2026-02-12	A	A-

InsiderStreet Scorecard

Proprietary multi-factor scorecard rating companies across seven fundamental dimensions — profitability, balance sheet strength, earnings quality, growth, value, momentum, and safety — each scored 0–100.

★ ★ ★ ★ ★ 82 Grade A+

Profitability

Balance Sheet

Earnings Quality

Growth

Value

Momentum

Safety

100

Cash Flow

The InsiderStreet Scorecard rates companies across eight dimensions: Profitability (margins, ROA, ROE), Balance Sheet (leverage, liquidity, coverage), Earnings Quality (accruals, cash conversion), Growth (revenue and earnings trajectory), Value (P/E, P/B, earnings yield, Graham criteria), Momentum (revenue and earnings acceleration), Safety (Altman Z-Score risk adjustment), and Cash Flow (operating cash flow quality, FCF conversion, cash coverage). The overall score blends 35% quality, 35% value, and 30% momentum, with a penalty for distress-zone Altman scores. GMED scores highest in Safety (100/100) and lowest in Value (56/100). An overall grade of A+ places GMED among the highest-quality companies in its peer group.

Risk & Quality Signals

Academic financial models used by institutional investors to assess bankruptcy risk, earnings manipulation, financial strength, and credit quality.

Altman Z-Score

10.85

Safe Zone

Piotroski F-Score

8/9

✓ ✓ ✓ ✓ ✓ ✓ ✗ ✓ ✓

Beneish M-Score

-2.69

Unlikely Manipulator

Ohlson O-Score

-12.74

Bankruptcy prob: 0.0%

Low Risk

Credit Rating

AA+

Score: 93.3/100

Trend: Deteriorating

Earnings Quality

75/100

OCF/NI: 1.70x

Accruals: -7.2%

The Altman Z-Score (1968) combines five ratios — working capital, retained earnings, EBIT, market value of equity, and sales, all relative to total assets or liabilities — into a single bankruptcy predictor. GMED scores 10.85, placing it in the Safe Zone (safe > 2.99, distress < 1.81). Bankruptcy is statistically unlikely within the next two years. The Piotroski F-Score (2000) is a 9-point binary checklist — four profitability tests (positive ROA, positive cash flow, improving ROA, cash flow exceeding net income), three leverage tests (declining debt ratio, improving current ratio, no share dilution), and two efficiency tests (improving gross margin, improving asset turnover). Each pass scores 1 point. GMED scores 8/9, signaling strong financial health across all three dimensions. The Beneish M-Score (1999) is an 8-variable model that detects earnings manipulation by comparing year-over-year changes in receivables, gross margins, asset quality, sales growth, depreciation, SG&A, leverage, and accruals. Scores above −1.78 statistically resemble past manipulators. GMED's score of -2.69 falls below this threshold, suggesting earnings are unlikely to be manipulated. The Ohlson O-Score (1980) is a 9-variable logistic regression that estimates bankruptcy probability using firm size, leverage, working capital, current ratio, profitability (ROA), cash flow coverage, negative equity flag, consecutive losses flag, and earnings trajectory. The raw score is converted to a probability via logistic transformation. GMED's implied 0.0% bankruptcy probability is well within safe territory. Our Credit Rating model scores companies on five weighted components — solvency (30%), earning power (25%), leverage (20%), liquidity (15%), and cash flow quality (10%) — then blends the absolute score with sector and industry peer rankings. For companies with large buyback programs, equity is adjusted by adding back cumulative 5-year repurchases (capped at 80% of FCF generated) to avoid penalizing shareholder-friendly capital allocation. GMED receives an estimated rating of AA+ (score: 93.3/100), with a deteriorating trend. The Earnings Quality score measures how well reported earnings are backed by real cash. It evaluates the operating cash flow to net income ratio (OCF/NI ≥ 1.0 means every dollar of earnings is cash-backed) and the accruals ratio (the gap between earnings and cash flow relative to assets — lower is better). GMED's score of 75/100 is high — cash flows strongly support reported earnings.

Valuation

Key valuation multiples comparing the stock's market price to its earnings, revenue, book value, and cash flows. Lower multiples may indicate relative undervaluation versus peers.

P/E

19.04x

PEG

0.37x

P/S

3.24x

P/B

2.15x

P/FCF

14.55x

P/OCF

11.99x

EV/EBITDA

11.91x

EV/Revenue

3.32x

EV/EBIT

15.69x

EV/FCF

13.90x

Earnings Yield

4.90%

FCF Yield

6.87%

Shareholder Yield

2.02%

Graham Number

$54.85

Equity-based multiples (P/E, P/B, P/FCF) compare the stock price to per-share fundamentals and are affected by capital structure. Enterprise value multiples (EV/EBITDA, EV/Revenue, EV/FCF) strip out debt and cash, making them more useful for cross-company comparisons regardless of how companies are financed. The Graham Number — √(22.5 × EPS × Book Value) — is Benjamin Graham's formula for the maximum price a defensive investor should pay. At 19.0x earnings, GMED trades at a reasonable valuation. Graham's intrinsic value formula yields $54.85 per share, 38% below the current price.

DuPont Decomposition (5-Factor)

The 5-factor DuPont framework breaks Return on Equity into its component drivers — tax efficiency, interest burden, operating profitability, asset utilization, and financial leverage — to reveal what truly drives shareholder returns.

Tax Burden

0.805

NI / EBT

Interest Burden

1.000

EBT / EBIT

EBIT Margin

0.211

EBIT / Rev

Asset Turnover

0.602

Rev / Assets

Equity Multiplier

1.153

Assets / Equity

ROE

11.8%

The 5-factor DuPont identity decomposes ROE as: Tax Burden × Interest Burden × EBIT Margin × Asset Turnover × Equity Multiplier = ROE. This reveals whether returns are driven by operating performance, financial leverage, or tax efficiency — three very different sources of profitability. GMED's ROE of 11.8% is driven by Asset Turnover (0.602), indicating efficient use of assets to generate revenue.

Graham-Dodd Adjusted Valuation

Our adaptation of Graham's growth formula (Fair P/E = 8.5 + 2g) from The Intelligent Investor. The classic version relies on analyst growth projections, which can be unreliable. This adjusted model substitutes the company's realized 3-year EPS CAGR — a backward-looking, verifiable measure of actual earnings power — grounding the valuation in demonstrated performance rather than forecasts.

Two adjustments we make, and why. Growth is capped at 15%. Graham defined g as expected growth over the next seven to ten years, not last year's rate. Across US companies since 1994 the median realized 7-year EPS growth is 5–8% regardless of how fast a company grew beforehand, and of 4,457 company-quarters that grew faster than 200%, none sustained it. Uncapped, the formula assigned fair multiples in the hundreds to companies that had never held that rate — and scored worse than simply reading the P/E. Capped, it carries real information. The verdict has three states, not two. Tested over 377,249 stock-months, this ratio only separates outcomes at its extremes: below 0.25 beat the universe by 1.3 points a year, above 3.0 lagged by 2.7, and everything in between sat inside a one-point band. Rather than call two-thirds of the market "undervalued" on a threshold of 1.0, we say Neutral where the model cannot tell — which is most of the time.

Adj. Growth Rate

15.00%

Fair P/E

38.50x

Intrinsic Value

$149.18

Price/Value

0.53x

Margin of Safety

47.04%

Premium

-47.04%

Assessment

Neutral

Graham's classic formula uses analyst-projected growth to estimate a fair P/E (8.5 + 2g). Our adjusted version replaces that projection with GMED's realized 15.0% 3-year EPS CAGR, capped at 15% — demonstrated performance rather than forecasts, held to a rate companies have historically sustained. GMED actually compounded EPS at 24.5% over three years; the model uses 15%, the highest rate it will extrapolate — of 4,457 company-quarters that grew faster than 200%, none sustained it over the following seven years. GMED trades at a -47% premium to its adjusted intrinsic value of $149.18, suggesting the market is pricing in future growth beyond what historical earnings support. The adjusted fair P/E of 38.5x compares to the current market P/E of 19.0x.

Profitability Trends

Historical profitability ratios tracking how efficiently the company converts revenue into returns for shareholders over time.

Leverage & Solvency Trends

Debt and liquidity metrics showing the company's financial leverage and ability to meet short-term and long-term obligations.

Efficiency & Working Capital Trends

Operating efficiency metrics measuring how quickly the company converts inventory to sales, collects receivables, and manages its cash conversion cycle.

Growth Trends (YoY %)

Year-over-year growth rates for key financial metrics, showing the trajectory of revenue, earnings, and cash flow generation.

Earnings Stability

R-squared of linear regression measuring how predictably revenue, earnings, and margins follow a trend over the trailing 5 years. 1.0 = perfectly predictable; lower values indicate erratic or cyclical behavior.

Monte Carlo Price Simulation

Geometric Brownian Motion with 1,000 antithetic paths over 1 year, seeded from 1800 days of historical volatility. Percentile bands show the range of statistically plausible outcomes — this is a statistical model, not a forecast.

Current Price

$75.58

Median 1Y

$75.11

5th Pctile

$40.05

95th Pctile

$140.77

Ann. Volatility

37.7%

Analyst Target

$92.67

25th–75th percentile 5th–95th percentile Median path Historical Analyst target

Executive Compensation

C-suite compensation breakdown including salary, stock awards, options, and incentive pay. The CEO-to-employee pay ratio and Gini coefficient measure pay distribution fairness.

C-Suite Compensation

Executive	Salary	Stock	Total
Daniel T. Scavilla, Former Chief Executive Officer and President	$284,616	$—	$5,316,939
Keith W. Pfeil, Chief Executive Officer and President	$479,467	$—	$4,400,159
David C. Paul, Chairman of the Board of Directors and Executive Chairman	$469,388	$—	$4,305,179
Kelly G. Huller, Executive Vice President, General Counsel and Corporate Secretary	$364,075	$—	$2,280,832
Kyle R Kline, Senior Vice President and Chief Financial Officer	$334,040	$—	$1,380,258

CEO Pay Ratio

24:1

CEO-to-Employee Pay Ratio

CEO Total Comp: $5,316,939

Avg Employee Cost (SGA/emp): $219,383

Employees: 6,000

C-Suite Pay Equality (Gini)

CEO Compensation Mix

Workforce & Productivity

Workforce efficiency metrics measuring revenue, profit, and R&D spend per employee — key indicators of operational leverage and human capital productivity.

Employees

6,000

+13.2% YoY

Revenue / Employee

$489,817

Rev: $2,938,900,000

Profit / Employee

$89,650

NI: $537,900,000

SGA / Employee

$219,383

Avg labor cost proxy

R&D / Employee

$30,833

Innovation spend

Scaling Efficiency

All Ratios & Metrics

Complete fundamental data with up to 20 periods of history, sparkline trends, and current values across 13 categories and 130+ financial metrics.

Profitability

Metric	Q3'21	Q4'21	Q1'22	Q2'22	Q3'22	Q4'22	Q1'23	Q2'23	Q3'23	Q4'23	Q1'24	Q2'24	Q3'24	Q4'24	Q1'25	Q2'25	Q3'25	Q4'25	Q1'26	Q2'26	Current
ROE	11.9%	9.2%	8.5%	9.3%	8.9%	10.6%	10.9%	11.1%	5.3%	4.2%	2.3%	1.4%	2.2%	2.5%	4.6%	8.6%	10.0%	12.3%	13.3%	11.8%	11.81%
ROA	10.8%	8.2%	7.6%	8.3%	8.0%	9.4%	9.7%	9.9%	4.3%	3.4%	1.9%	1.1%	1.8%	2.0%	3.8%	7.2%	8.3%	10.2%	11.6%	10.2%	10.25%
ROIC	15.3%	11.0%	10.3%	11.5%	10.9%	12.7%	13.2%	13.5%	3.3%	2.5%	1.5%	1.0%	2.2%	3.7%	5.5%	6.4%	8.2%	10.2%	11.5%	12.3%	12.27%
ROCE	12.8%	10.7%	10.2%	11.1%	10.9%	12.3%	12.4%	12.0%	4.8%	4.3%	4.2%	4.0%	3.9%	5.0%	6.6%	7.6%	9.5%	11.2%	12.1%	13.3%	13.28%
Gross Margin	74.5%	75.3%	74.3%	74.0%	74.2%	74.3%	74.4%	73.8%	64.7%	56.9%	60.2%	58.7%	56.8%	59.9%	67.3%	66.6%	63.3%	72.0%	69.2%	69.4%	69.42%
Operating Margin	23.2%	7.3%	20.1%	25.7%	23.5%	19.7%	20.4%	22.7%	0.1%	1.6%	1.3%	7.9%	7.7%	9.2%	16.2%	10.2%	17.6%	20.8%	21.5%	23.1%	23.10%
Net Margin	20.6%	6.0%	16.5%	20.7%	18.7%	18.2%	17.8%	19.8%	0.3%	2.4%	-1.2%	5.0%	8.3%	4.0%	12.6%	27.2%	15.5%	17.0%	16.4%	19.2%	19.20%
EBITDA Margin	30.9%	17.2%	28.4%	31.7%	30.2%	28.7%	27.4%	29.9%	22.5%	15.8%	14.0%	20.1%	18.5%	22.1%	27.4%	26.0%	28.0%	29.6%	29.9%	24.0%	24.04%
FCF Margin	24.0%	22.9%	20.2%	16.1%	11.8%	10.2%	10.9%	11.0%	10.5%	10.5%	8.0%	7.2%	11.9%	16.1%	20.6%	19.9%	20.9%	19.7%	19.5%	23.9%	23.87%
OCF Margin	29.8%	28.8%	26.8%	24.1%	19.1%	17.4%	17.5%	16.9%	16.5%	15.5%	12.8%	11.7%	16.7%	20.7%	25.7%	25.5%	25.8%	25.6%	25.1%	28.9%	28.95%
ROE 3Y Avg	snapshot only																				6.85%
ROE 5Y Avg	snapshot only																				7.99%
ROA 3Y Avg	snapshot only																				5.92%
ROIC 3Y Avg	snapshot only																				6.92%
ROIC Economic	snapshot only																				10.91%
Cash ROA	snapshot only																				16.59%
Cash ROIC	snapshot only																				21.25%
CROIC	snapshot only																				17.52%
NOPAT Margin	snapshot only																				16.71%
Pretax Margin	snapshot only																				21.14%
R&D / Revenue	snapshot only																				5.88%
SGA / Revenue	snapshot only																				43.07%
SBC / Revenue	snapshot only																				1.56%

Valuation

Metric	Q3'21	Q4'21	Q1'22	Q2'22	Q3'22	Q4'22	Q1'23	Q2'23	Q3'23	Q4'23	Q1'24	Q2'24	Q3'24	Q4'24	Q1'25	Q2'25	Q3'25	Q4'25	Q1'26	Q2'26	Current
P/E Ratio	42.77	50.42	54.10	37.27	38.92	39.92	28.77	29.66	36.24	60.29	108.97	230.65	107.93	112.21	55.14	22.59	18.30	22.27	20.29	20.39	19.043
P/S Ratio	8.50	7.85	7.99	5.93	6.05	7.42	5.41	5.52	4.67	4.72	3.82	4.19	3.98	4.59	4.07	3.07	2.80	4.08	3.84	3.47	3.242
P/B Ratio	4.66	4.32	4.30	3.40	3.42	4.11	3.02	3.05	1.37	1.85	1.85	2.36	2.43	2.77	2.50	1.88	1.76	2.62	2.52	2.29	2.146
P/FCF	35.36	34.29	39.54	36.90	51.20	72.70	49.46	50.06	44.33	44.84	47.85	58.26	33.62	28.52	19.77	15.42	13.38	20.70	19.67	14.55	14.547
P/OCF	28.55	27.23	29.83	24.57	31.67	42.53	30.94	32.72	28.21	30.42	29.93	35.83	23.80	22.19	15.85	12.04	10.84	15.90	15.29	11.99	11.993
EV/EBITDA	24.89	26.74	27.89	20.40	20.98	23.48	16.78	17.10	17.60	21.38	20.68	23.86	22.90	23.71	17.88	12.84	10.42	14.13	12.95	11.91	11.908
EV/Revenue	7.91	7.39	7.50	5.51	5.65	6.99	4.94	4.97	4.71	4.72	3.87	4.21	3.92	4.45	3.93	3.03	2.70	3.93	3.67	3.32	3.318
EV/EBIT	32.48	36.33	38.16	27.42	28.11	30.27	21.54	21.98	24.30	36.72	42.34	56.31	58.08	51.29	34.38	22.91	16.93	21.42	19.05	15.69	15.692
EV/FCF	32.91	32.27	37.10	34.29	47.77	68.48	45.15	45.00	44.75	44.85	48.46	58.49	33.08	27.65	19.05	15.21	12.91	19.94	18.82	13.90	13.902
Earnings Yield	2.3%	2.0%	1.8%	2.7%	2.6%	2.5%	3.5%	3.4%	2.8%	1.7%	0.9%	0.4%	0.9%	0.9%	1.8%	4.4%	5.5%	4.5%	4.9%	4.9%	4.90%
FCF Yield	2.8%	2.9%	2.5%	2.7%	2.0%	1.4%	2.0%	2.0%	2.3%	2.2%	2.1%	1.7%	3.0%	3.5%	5.1%	6.5%	7.5%	4.8%	5.1%	6.9%	6.87%
PEG Ratio	snapshot only																				0.370
Price/Tangible Book	snapshot only																				4.139
EV/OCF	snapshot only																				11.462
EV/Gross Profit	snapshot only																				4.840
Acquirers Multiple	snapshot only																				15.987
Shareholder Yield	snapshot only																				2.02%
Graham Number	snapshot only																				$54.85

Leverage & Solvency

Metric	Q3'21	Q4'21	Q1'22	Q2'22	Q3'22	Q4'22	Q1'23	Q2'23	Q3'23	Q4'23	Q1'24	Q2'24	Q3'24	Q4'24	Q1'25	Q2'25	Q3'25	Q4'25	Q1'26	Q2'26	Current
Current Ratio	8.00	6.17	6.48	6.10	6.33	6.18	6.39	7.80	4.47	4.88	2.33	2.42	2.51	2.54	4.45	4.07	4.13	4.26	4.56	4.62	4.622
Quick Ratio	6.09	4.48	4.68	4.28	4.39	4.30	4.47	5.63	2.36	2.72	1.29	1.45	1.64	1.77	2.72	2.26	2.47	2.74	2.95	2.93	2.930
Debt/Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.12	0.13	0.13	0.13	0.13	0.13	0.02	0.03	0.03	0.03	0.02	0.02	0.023
Net Debt/Equity	-0.32	-0.25	-0.27	-0.24	-0.23	-0.24	-0.26	-0.31	0.01	0.00	0.02	0.01	-0.04	-0.08	-0.09	-0.03	-0.06	-0.10	-0.11	-0.10	-0.101
Debt/Assets	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.10	0.10	0.11	0.11	0.11	0.10	0.02	0.02	0.02	0.02	0.02	0.02	0.020
Debt/EBITDA	0.00	0.00	0.00	0.00	0.00	0.02	0.00	0.00	1.59	1.50	1.48	1.34	1.26	1.14	0.17	0.20	0.17	0.15	0.13	0.13	0.127
Net Debt/EBITDA	-1.85	-1.68	-1.83	-1.55	-1.51	-1.45	-1.60	-1.92	0.16	0.01	0.26	0.09	-0.38	-0.75	-0.67	-0.18	-0.38	-0.54	-0.58	-0.55	-0.552
Interest Coverage	22.24	20.96	20.69	21.60	18.47	16.60	13.49	10.32	11.82	11.62	13.60	24.56	22.06	37.53	73.10	218.19	542.24	—	—	—	—
Equity Multiplier	1.11	1.12	1.12	1.13	1.12	1.12	1.12	1.11	1.28	1.27	1.26	1.26	1.25	1.26	1.15	1.15	1.16	1.16	1.15	1.15	1.151
Cash Ratio	snapshot only																				1.242
Cash to Debt	snapshot only																				5.352
FCF to Debt	snapshot only																				6.750
Defensive Interval	snapshot only																				323.7 days

Efficiency & Turnover

Metric	Q3'21	Q4'21	Q1'22	Q2'22	Q3'22	Q4'22	Q1'23	Q2'23	Q3'23	Q4'23	Q1'24	Q2'24	Q3'24	Q4'24	Q1'25	Q2'25	Q3'25	Q4'25	Q1'26	Q2'26	Current
Asset Turnover	0.55	0.53	0.51	0.52	0.51	0.51	0.52	0.53	0.33	0.44	0.54	0.62	0.47	0.49	0.52	0.53	0.54	0.56	0.61	0.60	0.602
Inventory Turnover	1.02	1.03	1.00	1.00	0.99	0.98	0.96	0.94	0.60	0.96	1.26	1.63	1.28	1.37	1.34	1.27	1.33	1.35	1.39	1.25	1.250
Receivables Turnover	6.22	6.26	5.88	5.43	5.46	5.42	5.50	5.07	3.50	4.38	5.01	5.25	4.58	4.75	4.70	4.29	4.59	4.75	5.08	4.82	4.824
Payables Turnover	9.40	11.91	10.04	8.94	9.68	9.09	8.35	8.33	5.94	11.82	15.92	17.87	14.36	15.71	16.01	12.68	13.68	11.01	11.27	10.20	10.195
DSO	59	58	62	67	67	67	66	72	104	83	73	70	80	77	78	85	80	77	72	76	75.7 days
DIO	357	356	364	366	370	371	381	387	613	382	289	224	285	266	273	288	275	270	263	292	292.1 days
DPO	39	31	36	41	38	40	44	44	61	31	23	20	25	23	23	29	27	33	32	36	35.8 days
Cash Conversion Cycle	377	383	390	392	399	398	404	416	656	434	339	273	340	319	328	344	327	314	303	332	331.9 days
Fixed Asset Turnover	snapshot only																				5.306
Operating Cycle	snapshot only																				367.7 days
Cash Velocity	snapshot only																				5.284
Capital Intensity	snapshot only																				1.745

Growth (YoY)

Metric	Q3'21	Q4'21	Q1'22	Q2'22	Q3'22	Q4'22	Q1'23	Q2'23	Q3'23	Q4'23	Q1'24	Q2'24	Q3'24	Q4'24	Q1'25	Q2'25	Q3'25	Q4'25	Q1'26	Q2'26	Current
Revenue	22.7%	21.4%	16.4%	5.0%	6.0%	6.8%	11.2%	12.6%	22.8%	53.3%	77.6%	1.0%	1.0%	60.6%	32.3%	17.4%	11.7%	16.7%	23.5%	19.7%	19.74%
Net Income	97.2%	45.9%	16.7%	-15.8%	-17.0%	27.5%	41.8%	31.8%	1.7%	-35.4%	-66.9%	-80.1%	-42.0%	-16.2%	1.8%	7.8%	3.6%	4.2%	2.2%	50.1%	50.14%
EPS	89.8%	42.0%	14.8%	-15.3%	-14.6%	29.9%	44.4%	33.3%	-10.5%	-52.5%	-75.0%	-85.2%	-51.6%	-16.6%	1.7%	7.8%	3.7%	4.3%	2.2%	48.3%	48.30%
FCF	1.1%	62.3%	17.7%	-22.8%	-47.9%	-52.4%	-39.7%	-22.7%	9.4%	58.2%	29.7%	33.0%	1.3%	1.5%	2.4%	2.2%	97.3%	42.8%	17.0%	43.7%	43.67%
EBITDA	84.0%	48.4%	25.0%	-11.0%	-10.2%	15.0%	21.8%	21.0%	22.1%	13.8%	12.9%	23.9%	29.3%	36.3%	55.2%	56.8%	69.2%	73.0%	59.5%	41.6%	41.61%
Op. Income	1.1%	54.3%	19.1%	-11.1%	-9.5%	32.6%	45.2%	27.2%	-7.8%	-41.6%	-64.4%	-71.2%	-34.6%	24.7%	2.0%	3.1%	2.2%	1.9%	1.1%	1.3%	1.32%
OCF Growth	snapshot only																				36.05%
Asset Growth	snapshot only																				10.63%
Equity Growth	snapshot only																				11.01%
Debt Growth	snapshot only																				-8.18%
Shares Change	snapshot only																				1.24%

Growth (CAGR)

Metric	Q3'21	Q4'21	Q1'22	Q2'22	Q3'22	Q4'22	Q1'23	Q2'23	Q3'23	Q4'23	Q1'24	Q2'24	Q3'24	Q4'24	Q1'25	Q2'25	Q3'25	Q4'25	Q1'26	Q2'26	Current
Revenue 3Y	10.8%	10.4%	10.0%	9.5%	9.1%	9.2%	10.5%	13.6%	16.9%	25.7%	32.0%	34.1%	38.1%	38.0%	37.7%	39.2%	40.5%	42.2%	42.6%	42.1%	42.06%
Revenue 5Y	11.1%	11.2%	10.6%	10.3%	10.3%	10.0%	10.3%	10.2%	12.1%	17.1%	21.3%	24.7%	26.4%	26.3%	25.9%	28.6%	29.3%	30.1%	30.3%	27.7%	27.65%
EPS 3Y	8.2%	-2.4%	-2.7%	2.2%	2.2%	7.3%	10.8%	30.1%	13.2%	-4.3%	-25.4%	-44.9%	-28.2%	-19.9%	-0.9%	20.1%	26.9%	28.2%	29.2%	24.5%	24.51%
EPS 5Y	8.0%	5.8%	4.8%	6.4%	6.9%	11.3%	10.9%	8.7%	-0.6%	-10.5%	-19.8%	-26.8%	-14.3%	-13.3%	-1.7%	23.4%	27.1%	31.2%	29.0%	16.9%	16.85%
Net Income 3Y	9.1%	-1.6%	-1.9%	2.6%	2.0%	7.0%	10.8%	31.9%	18.5%	6.3%	-18.2%	-39.5%	-21.2%	-11.6%	9.3%	32.0%	39.8%	41.4%	42.9%	37.9%	37.87%
Net Income 5Y	9.7%	7.4%	6.2%	7.5%	7.7%	12.1%	11.2%	8.7%	1.8%	-4.7%	-15.0%	-22.3%	-9.0%	-7.9%	4.6%	32.0%	34.9%	39.4%	37.0%	23.8%	23.81%
EBITDA 3Y	11.1%	6.9%	6.9%	7.8%	7.1%	10.6%	12.9%	27.7%	26.4%	24.8%	19.8%	10.1%	12.3%	21.3%	28.8%	33.0%	38.8%	39.0%	40.9%	40.1%	40.12%
EBITDA 5Y	8.1%	6.5%	5.6%	5.6%	6.0%	8.2%	8.7%	8.1%	8.5%	9.8%	11.0%	13.4%	14.1%	16.0%	20.3%	32.3%	34.6%	35.6%	33.6%	24.3%	24.26%
Gross Profit 3Y	9.3%	9.1%	8.7%	8.2%	7.9%	7.8%	9.4%	13.7%	15.8%	21.3%	25.1%	24.5%	27.0%	27.3%	28.4%	31.4%	33.8%	37.7%	38.4%	38.4%	38.38%
Gross Profit 5Y	10.6%	10.9%	10.2%	9.9%	9.9%	9.4%	9.6%	9.3%	10.1%	13.0%	16.1%	18.4%	19.5%	19.6%	20.2%	24.4%	25.9%	28.2%	28.4%	25.5%	25.55%
Op. Income 3Y	6.8%	0.5%	0.6%	4.8%	5.1%	9.8%	13.4%	35.5%	19.8%	6.1%	-14.9%	-31.2%	-18.3%	-1.2%	15.9%	14.9%	24.2%	28.2%	31.9%	40.3%	40.30%
Op. Income 5Y	4.0%	2.2%	1.6%	4.2%	5.2%	7.1%	7.3%	6.6%	0.3%	-4.7%	-12.0%	-15.9%	-6.9%	-0.7%	9.3%	24.3%	29.1%	33.9%	31.8%	25.6%	25.58%
FCF 3Y	21.5%	21.6%	27.8%	23.8%	9.5%	1.0%	2.0%	1.6%	6.3%	6.9%	-2.8%	-7.4%	9.1%	22.7%	38.6%	49.4%	70.0%	77.0%	72.9%	83.7%	83.71%
FCF 5Y	12.9%	10.9%	8.8%	4.2%	0.6%	-0.7%	2.0%	1.5%	0.4%	6.3%	10.3%	14.3%	26.7%	32.0%	36.3%	35.3%	40.1%	33.8%	29.7%	29.9%	29.92%
OCF 3Y	15.4%	15.0%	15.2%	14.2%	5.6%	1.2%	2.2%	1.8%	5.5%	7.0%	3.3%	0.7%	14.0%	23.5%	35.9%	41.7%	55.4%	61.6%	60.8%	70.0%	70.02%
OCF 5Y	11.3%	10.0%	8.6%	6.3%	2.7%	2.3%	3.4%	2.3%	2.2%	6.0%	7.6%	10.6%	20.7%	24.8%	29.8%	30.7%	32.8%	30.5%	28.7%	28.9%	28.86%
Assets 3Y	15.5%	14.6%	14.4%	11.2%	10.8%	10.7%	13.3%	14.7%	51.5%	44.7%	41.7%	39.7%	38.6%	39.0%	33.1%	37.3%	37.1%	36.7%	36.3%	35.4%	35.37%
Assets 5Y	16.2%	16.1%	15.8%	14.0%	13.8%	14.0%	13.8%	13.1%	34.0%	31.4%	29.9%	29.1%	28.5%	27.9%	26.1%	27.6%	27.0%	25.9%	25.6%	24.6%	24.56%
Equity 3Y	14.6%	13.7%	13.0%	9.7%	9.6%	9.6%	12.0%	14.1%	43.5%	38.5%	35.9%	34.4%	33.3%	33.9%	31.8%	36.2%	35.6%	35.3%	35.2%	33.9%	33.93%
Book Value 3Y	13.7%	12.7%	12.0%	9.2%	9.9%	9.9%	12.0%	12.5%	37.1%	24.6%	23.8%	22.4%	21.4%	21.4%	19.5%	24.0%	23.2%	22.6%	22.3%	20.9%	20.95%
Dividend 3Y	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—

Growth Quality

Metric	Q3'21	Q4'21	Q1'22	Q2'22	Q3'22	Q4'22	Q1'23	Q2'23	Q3'23	Q4'23	Q1'24	Q2'24	Q3'24	Q4'24	Q1'25	Q2'25	Q3'25	Q4'25	Q1'26	Q2'26	Current
Revenue Stability	0.93	0.94	0.97	0.94	0.94	0.94	0.96	0.94	0.90	0.75	0.68	0.62	0.63	0.74	0.80	0.81	0.82	0.89	0.92	0.90	0.900
Earnings Stability	0.25	0.17	0.31	0.27	0.26	0.30	0.43	0.40	0.11	0.00	0.08	0.03	0.03	0.06	0.01	0.22	0.35	0.39	0.44	0.45	0.454
Margin Stability	0.98	0.97	0.98	0.98	0.98	0.98	0.98	0.98	0.97	0.93	0.92	0.90	0.89	0.89	0.89	0.90	0.90	0.91	0.91	0.90	0.902
Rev. Growth Consistency	0.50	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.000
Earn. Growth Consistency	0.50	0.50	0.50	0.00	0.00	1.00	1.00	0.50	0.50	0.00	0.00	0.00	0.00	0.00	0.50	0.50	0.50	0.50	1.00	1.00	1.000
FCF Positive Streak	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
Earnings Persistence	0.50	0.82	0.93	0.94	0.93	0.89	0.83	0.87	0.99	0.86	0.50	0.50	0.83	0.94	0.50	0.50	0.50	0.50	0.50	0.50	0.500
Earnings Smoothness	0.35	0.63	0.85	0.83	0.81	0.76	0.65	0.73	0.98	0.57	0.00	0.00	0.47	0.82	0.06	0.00	0.00	0.00	0.00	0.60	0.599
ROE Trend	0.02	-0.00	-0.01	0.00	0.00	0.03	0.03	0.00	-0.06	-0.06	-0.08	-0.09	-0.04	-0.04	-0.02	0.03	0.07	0.09	0.09	0.07	0.066
Gross Margin Trend	-0.00	0.00	0.00	0.00	0.01	0.00	0.00	-0.00	-0.03	-0.10	-0.12	-0.15	-0.15	-0.11	-0.08	-0.04	-0.00	0.05	0.06	0.07	0.073
FCF Margin Trend	0.11	0.08	0.03	-0.03	-0.07	-0.10	-0.09	-0.08	-0.07	-0.06	-0.08	-0.06	0.01	0.06	0.11	0.11	0.10	0.06	0.05	0.10	0.103
Sustainable Growth Rate	11.9%	9.2%	8.5%	9.3%	8.9%	10.6%	10.9%	11.1%	5.3%	4.2%	2.3%	1.4%	2.2%	2.5%	4.6%	8.6%	10.0%	12.3%	13.3%	11.8%	11.81%
Internal Growth Rate	12.2%	8.9%	8.2%	9.0%	8.7%	10.4%	10.7%	11.0%	4.5%	3.6%	1.9%	1.1%	1.8%	2.0%	4.0%	7.7%	9.1%	11.3%	13.1%	11.4%	11.42%

Cash Flow Quality

Metric	Q3'21	Q4'21	Q1'22	Q2'22	Q3'22	Q4'22	Q1'23	Q2'23	Q3'23	Q4'23	Q1'24	Q2'24	Q3'24	Q4'24	Q1'25	Q2'25	Q3'25	Q4'25	Q1'26	Q2'26	Current
OCF/Net Income	1.50	1.85	1.81	1.52	1.23	0.94	0.93	0.91	1.28	1.98	3.64	6.44	4.53	5.06	3.48	1.88	1.69	1.40	1.33	1.70	1.700
FCF/OCF	0.81	0.79	0.75	0.67	0.62	0.59	0.63	0.65	0.64	0.68	0.63	0.62	0.71	0.78	0.80	0.78	0.81	0.77	0.78	0.82	0.824
FCF/Net Income	snapshot only																				1.402
OCF/EBITDA	snapshot only																				1.039
CapEx/Revenue	5.7%	5.9%	6.6%	8.1%	7.3%	7.2%	6.6%	5.9%	6.0%	5.0%	4.8%	4.5%	4.9%	4.6%	5.1%	5.6%	4.9%	5.9%	5.6%	5.1%	5.08%
CapEx/Depreciation	snapshot only																				0.756
Accruals Ratio	-0.05	-0.07	-0.06	-0.04	-0.02	0.01	0.01	0.01	-0.01	-0.03	-0.05	-0.06	-0.06	-0.08	-0.10	-0.06	-0.06	-0.04	-0.04	-0.07	-0.072
Sloan Accruals	snapshot only																				0.042
Cash Flow Adequacy	snapshot only																				5.697
Earnings Quality Score	snapshot only																				0.750

Dividends & Buybacks

Metric	Q3'21	Q4'21	Q1'22	Q2'22	Q3'22	Q4'22	Q1'23	Q2'23	Q3'23	Q4'23	Q1'24	Q2'24	Q3'24	Q4'24	Q1'25	Q2'25	Q3'25	Q4'25	Q1'26	Q2'26	Current
Dividend Yield	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.00%
Dividend/Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Payout Ratio	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.00%
FCF Payout Ratio	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.00%
Total Payout Ratio	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	1.8%	4.6%	7.6%	3.4%	83.3%	1.0%	60.7%	60.5%	55.9%	18.7%	41.3%	41.28%
Div. Increase Streak	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Chowder Number	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Buyback Yield	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	3.0%	4.3%	3.3%	3.1%	0.7%	1.9%	2.7%	3.3%	2.5%	0.9%	2.0%	2.02%
Net Buyback Yield	-0.8%	-0.5%	-0.4%	-0.1%	-0.1%	0.0%	0.0%	0.0%	0.0%	3.0%	4.3%	3.3%	3.1%	0.7%	1.9%	2.7%	3.2%	2.4%	0.6%	1.6%	1.58%
Total Shareholder Return	-0.8%	-0.5%	-0.4%	-0.1%	-0.1%	0.0%	0.0%	0.0%	0.0%	3.0%	4.3%	3.3%	3.1%	0.7%	1.9%	2.7%	3.2%	2.4%	0.6%	1.6%	1.58%

DuPont Factors

Metric	Q3'21	Q4'21	Q1'22	Q2'22	Q3'22	Q4'22	Q1'23	Q2'23	Q3'23	Q4'23	Q1'24	Q2'24	Q3'24	Q4'24	Q1'25	Q2'25	Q3'25	Q4'25	Q1'26	Q2'26	Current
Tax Burden (NI/EBT)	0.84	0.83	0.82	0.80	0.77	0.78	0.78	0.78	0.78	0.74	0.71	0.61	0.76	0.85	0.80	0.95	0.92	0.88	0.88	0.81	0.805
Interest Burden (EBT/EBIT)	0.97	0.93	0.91	0.99	1.00	1.03	1.05	1.06	0.85	0.82	0.54	0.40	0.72	0.55	0.81	1.08	1.04	1.13	1.11	1.00	1.000
EBIT Margin	0.24	0.20	0.20	0.20	0.20	0.23	0.23	0.23	0.19	0.13	0.09	0.07	0.07	0.09	0.11	0.13	0.16	0.18	0.19	0.21	0.211
Asset Turnover	0.55	0.53	0.51	0.52	0.51	0.51	0.52	0.53	0.33	0.44	0.54	0.62	0.47	0.49	0.52	0.53	0.54	0.56	0.61	0.60	0.602
Equity Multiplier	1.10	1.12	1.12	1.12	1.12	1.12	1.12	1.12	1.23	1.23	1.22	1.21	1.26	1.26	1.21	1.20	1.20	1.21	1.15	1.15	1.153

Per Share

Metric	Q3'21	Q4'21	Q1'22	Q2'22	Q3'22	Q4'22	Q1'23	Q2'23	Q3'23	Q4'23	Q1'24	Q2'24	Q3'24	Q4'24	Q1'25	Q2'25	Q3'25	Q4'25	Q1'26	Q2'26	Current
EPS (Diluted TTM)	$1.79	$1.43	$1.36	$1.51	$1.53	$1.86	$1.97	$2.01	$1.37	$0.88	$0.49	$0.30	$0.66	$0.74	$1.33	$2.61	$3.13	$3.92	$4.25	$3.87	$3.87
Book Value/Share	$16.46	$16.71	$17.15	$16.51	$17.39	$18.06	$18.74	$19.50	$36.33	$28.76	$28.98	$29.03	$29.48	$29.90	$29.25	$31.47	$32.49	$33.33	$34.24	$34.51	$35.23
Tangible Book/Share	$14.16	$14.33	$14.82	$14.16	$15.07	$15.51	$16.21	$17.01	$15.65	$11.79	$11.70	$12.09	$13.00	$13.96	$13.47	$15.12	$16.18	$17.44	$18.62	$19.09	$19.09
Revenue/Share	$9.02	$9.20	$9.24	$9.47	$9.84	$10.01	$10.46	$10.78	$10.64	$11.28	$14.03	$16.33	$17.95	$18.03	$17.96	$19.24	$20.46	$21.42	$22.44	$22.76	$23.23
FCF/Share	$2.17	$2.11	$1.87	$1.52	$1.16	$1.02	$1.15	$1.19	$1.12	$1.19	$1.12	$1.18	$2.13	$2.90	$3.70	$3.83	$4.28	$4.22	$4.38	$5.43	$5.54
OCF/Share	$2.68	$2.65	$2.47	$2.28	$1.88	$1.75	$1.83	$1.82	$1.76	$1.75	$1.79	$1.91	$3.01	$3.73	$4.62	$4.90	$5.28	$5.49	$5.63	$6.59	$6.73
Cash/Share	$5.30	$4.26	$4.55	$3.97	$4.00	$4.36	$4.94	$6.02	$4.07	$3.72	$3.21	$3.60	$5.03	$6.37	$3.30	$1.68	$2.88	$4.06	$4.56	$4.31	$4.40
EBITDA/Share	$2.87	$2.54	$2.48	$2.56	$2.65	$2.98	$3.08	$3.13	$2.85	$2.49	$2.63	$2.88	$3.07	$3.38	$3.95	$4.53	$5.30	$5.95	$6.37	$6.34	$6.34
Debt/Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.06	$0.00	$0.00	$4.54	$3.74	$3.88	$3.86	$3.87	$3.84	$0.66	$0.89	$0.88	$0.86	$0.83	$0.80	$0.80
Net Debt/Share	$-5.30	$-4.26	$-4.55	$-3.97	$-4.00	$-4.31	$-4.94	$-6.02	$0.47	$0.02	$0.67	$0.27	$-1.16	$-2.53	$-2.64	$-0.79	$-2.00	$-3.20	$-3.72	$-3.50	$-3.50

Academic Models

Metric	Q3'21	Q4'21	Q1'22	Q2'22	Q3'22	Q4'22	Q1'23	Q2'23	Q3'23	Q4'23	Q1'24	Q2'24	Q3'24	Q4'24	Q1'25	Q2'25	Q3'25	Q4'25	Q1'26	Q2'26	Current
Altman Z-Score	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	10.845
Altman Z-Prime	snapshot only																				19.727
Piotroski F-Score	6	6	5	5	5	6	6	6	3	3	4	4	4	6	8	9	9	9	8	8	8
Beneish M-Score	-2.46	-2.59	-2.64	-2.57	-2.35	-2.20	-2.19	-2.28	-1.15	-0.99	-1.07	-0.98	-2.42	-2.76	-2.99	-2.75	-2.64	-2.65	-2.32	-2.69	-2.690
Ohlson O-Score	snapshot only																				-12.743
ROIC (Greenblatt)	snapshot only																				28.55%
Net-Net WC	snapshot only																				$10.82
EVA	snapshot only																				$97125113.52

Credit

Metric	Q3'21	Q4'21	Q1'22	Q2'22	Q3'22	Q4'22	Q1'23	Q2'23	Q3'23	Q4'23	Q1'24	Q2'24	Q3'24	Q4'24	Q1'25	Q2'25	Q3'25	Q4'25	Q1'26	Q2'26	Current
Credit Rating	snapshot only																				AA+
Credit Score	89.00	89.00	89.00	89.00	89.00	95.80	89.00	89.00	87.80	92.30	88.11	91.93	94.78	94.63	96.58	96.37	95.98	93.27	92.77	93.26	93.263
Credit Grade	snapshot only																				2
Credit Trend	snapshot only																				-3.109
Implied Spread (bps)	snapshot only																				65.000
Industry Credit Rank	snapshot only																				87
Sector Credit Rank	snapshot only																				90

GMED NYSE

Edge Score

Analyst Insights

Financial Rating

InsiderStreet Scorecard

Risk & Quality Signals

Valuation

DuPont Decomposition (5-Factor)

Graham-Dodd Adjusted Valuation

Profitability Trends

Leverage & Solvency Trends

Efficiency & Working Capital Trends

Growth Trends (YoY %)

Earnings Stability

Monte Carlo Price Simulation

Executive Compensation

C-Suite Compensation

CEO Pay Ratio

C-Suite Pay Equality (Gini)

CEO Compensation Mix

Workforce & Productivity

Scaling Efficiency

Sign in to InsiderStreet